TITAN Time to Integrilin Therapy in Acute myocardial infarctioN (TITAN)-TIMI 34.

Slides:



Advertisements
Similar presentations
GUSTO-IV AMI G lobal U se of S trategies T o Open O ccluded Coronary Arteries in AMI.
Advertisements

Unstable Angina: Embolism Can Occur Prior to PCI Thrombus in proximal RCA Stain of muscle before injection begins: TIMI Myocardial perfusion grade 1 CM.
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
Comparison of AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients with Acute Myocardial Infarction: the JETSTENT trial David.
Comparison of AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients with Acute Myocardial Infarction: the JETSTENT trial David.
Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus conservative strategy. PRAGUE 13 trial O.
Anterior Depressions Angiographic and Clinical Outcomes Among Patients with Acute Coronary Syndromes Presenting with Anterior ST-Segment Depressions C.
STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,
Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
The AiMI Trial Arshad Ali, MD, David Cox, MD, Nabil Dib, MD, Bruce Brodie, MD, Daniel Berman, MD, Navin Gupta, MD, Kevin Browne, MD, Robert Iwaoka, MD,
Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.
Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction Results of the Antithrombotics.
Around-the-Clock Primary Angioplasty: A Process of Care Analysis Comparing Off-Hours and Normal Hours Treatment of Acute STEMI R Leung, D Lundberg, D Galbraith,
GP IIb/IIIa Inhibition in STEMI: Growing Clinical Trial Evidence.
ACS and Thrombosis in the Emergency Setting
Clinical Trial Results. org C. Michael Gibson, M.S., M.D. Director TIMI Data Coordinating Center Invasive Cardiologist Beth Israel Deaconess Medical Center.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Presentation at a Non PCI Facility Requiring Transfer Does NOT Worsen Long-term Prognosis in Patients With STEMI Undergoing Primary Angioplasty. The HORIZONS-AMI.
HORIZONS AMI Trial H armonizing O utcomes with R evascular IZ ati ON and S tents In A cute M ycoardial I nfarction H armonizing O utcomes with R evascular.
TARGET and TACTICS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
Baran KW August 28, 2000 Kenneth W. Baran MD for the LIMIT AMI Investigators St. Paul Heart Clinic, St. Paul, MN, USA Sponsor: Genentech Inc., South San.
Beyond TIMI 3 Flow CTFC < 14 CTFC > % (n=41) (n = 18/640) (n =35/563) 2.8% p= “TIMI 4” Flow TIMI 3 Flow 14 < CTFC < % % Risk of In Hospital.
The INT egrelin and E noxaparin R andomized assessment of A cute C oronary syndrome Treatment T rial Sponsored by the Canadian Heart Research Centre, Key.
RP Giugliano MD, SM; MT Roe, MD, MHS; RA Harrington MD; CM Gibson, MS, MD; U Zeymer, MD; F Van de Werf, MD, PhD; KW Baran, MD; HP Hobbach, MD; LH Woodlief,
TIMI 14 Antman et al. Circ 99: 2720,1999 Phases of Trial ControlInvestigational Accel tPA Accel tPA Accel tPA rPA ( U) rPA ( U) No lytic Abx.
The 90 Minute Wall: 60% Rates of TIMI Grade 3 Flow % TIMI 3 Flow.
The Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented.
TIMI 10A Protocol Design TNK- tPA Bolus ASA + IV Heparin (APTT 55-85) Follow-up Hosp. Discharge to 30 days Pt. with Acute MI < 12h End Points: Pharmacokinetics.
Proof of Concept #1: Occluded Arteries Cause Acute MI Proof of Concept #1: Occluded Arteries Cause Acute MI Proof of Concept #2: Drugs (in this case IC.
A Prospective, Randomized Evaluation of Supersaturated Oxygen Therapy After Percutaneous Coronary Intervention in Acute Anterior Myocardial Infarction.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
Trial Vignettes 1-3 Mark Mason Harefield Hospital Royal Brompton and Harefield NHS Trust.
PROTECT: What Have We Learned Lesson 2: TMPG is associated with clinical and biomarker outcomes following PCI.
Randomized Trial to Evaluate the Relative PROTECTion against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Anti-Platelet and Anti-Thrombotic.
Randomized Early versus Late AbciXimab in Acute Myocardial Infarction treated with primary coronary intervention (RELAx-AMI Trial) Mauro Maioli M.D., Francesco.
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
High-risk ST elevation MI patients (>4 mm elevation), Sx < 12 hrs 5 PCI centers (n=443) and 22 referring hospitals (n=1,129), transfer in < 3 hrs High-risk.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.
Relationship of the TIMI Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to Long-Term Outcomes After Thrombolytic.
Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented at.
Randomized Early versus Late Abciximab in Acute Myocardial Infarction Treated With Primary Coronary Intervention (RELAx-AMI Trial) Mauro Maioli, MD, Francesco.
Dartmouth Hitchcock Medical Center
For the HORIZONS-AMI Investigators
FINESSE: Study Design Acute ST Elevation MI (or New LBBB) within 6h pain onset Presenting at Hub or Spoke with estimated time to Cath between 1 and 4 hours.
Intra Coronary AdjunctivE Tenecteplase During Primary PCI for STEMI:
TITAN Time to Integrilin Therapy in Acute myocardial infarctioN (TITAN)-TIMI 34 Dr. Eugene Braunwald was the study chairman and Ms. Carolyn McCabe the.
European Society of Cardiology 2003
The HORIZONS-AMI Trial
For the HORIZONS-AMI Investigators
For the HORIZONS-AMI Investigators
PROTECT – TIMI 30 Trial Randomized Trial to Evaluate the Relative PROTECTion against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Anti-Platelet.
Published in the European Heart Journal
TIMI IIIA Protocol Design 391 Patients with Unstable Angina / NQWMI
In STEMI Complete Reperfusion (TFG 3, TMPG 3, ST Res  70%) is Associated with a Greater Percent of Receptors Occupied by Integrilin 52.0% % Pts With Complete.
52.0% Complete Resolution TFG 3 TMPG 3 ST Resolution  70% p=0.006
Secondary Efficacy Endpoints
TIMI Myocardial Perfusion (TMP) Grades Dye strongly persistent
What oral antiplatelet therapy would you choose?
Dye strongly persistent
Maintenance of Long-Term Clinical Benefit with
A New Angiographic Risk Score in Facilitated PCI
Dye strongly persistent
Association of Troponin Elevation with Risk of Mortality in Acute Coronary Syndromes Mortality at 42 Days  % A study by Antman and.
European Heart Journal Advance Access
INTRO AMI. INTEGRILIN AND. REDUCED DOSE. OF THROMBOLYTIC IN. ACUTE
GUSTO 1 Trial 41,000 patients enrolled, landmark study
Dye strongly persistent
Presentation transcript:

TITAN Time to Integrilin Therapy in Acute myocardial infarctioN (TITAN)-TIMI 34

TITAN-TIMI 34: Goal To answer the following question: Among patients intended to undergo primary PCI, does a strategy of early initiation of eptifibatide in the ER prior to primary PCI yield superior pre-PCI angiographic outcomes compared to a strategy of initiating eptifibatide in the cardiac catheterization laboratory after diagnostic angiography? © TIMI Duplication prohibited by law

TITAN-TIMI 34: Trial Organization TIMI Study GroupEugene Braunwald, M.D. (Chairman) Brigham and Women’sC. Michael Gibson, M.S., M.D. (Principal Investigator) HospitalCarolyn McCabe, B.S. (Director) Ajay Kirtane, M.D. (Co-Investigator) Christopher P. Cannon, M.D. (Co-Investigator) Polly Fish, B.S. (Project Manager) Data Coordinating Center TIMI Data Coordinating Center Sabina A. Murphy, M.P.H. (Director Biostatistics) Jacqueline L. Buros, B.A. (Director Data Management) Angiographic Core LabTIMI Angiographic Core Lab Ajay Kirtane, M.D. (Principal Investigator) Lauren N. Ciaglo, B.A. EKG Core LabTIMI EKG Core Lab Benjamin Scirica, M.D. (Director) © TIMI Duplication prohibited by law

Primary PCI STEMI < 6 HRS Undergoing Primary PCI (n=343) TITAN TIMI 34: Study Design RANDOMIZE Open Label RANDOMIZE ASA mg po HEPARIN 60 U/kg bolus (Max 4000U) and 7U/kg infusion (Max 800 U/hr) “EARLY ER EPTIFIBATIDE” “CATH LAB EPTIFIBATIDE” EPTIFIBATIDE 180/2.0/180 TRANSFER TO CATH LAB DIAGNOSTIC ANGIO PRIMARY ENDPOINT: Pre PCI TIMI Frame Count EPTIFIBATIDE 180/2.0/180 TRANSFER TO CATH LAB DIAGNOSTIC ANGIO © TIMI Duplication prohibited by law

TITAN-TIMI 34: Enrollment Criteria Inclusion Criteria: > 18 years of age Clinical diagnosis of AMI ( ischemic pain > 20 min. ) Onset of symptoms < 6 hours ST elevation > 1 mm in 2 contiguous limb leads or >2 mm in 2 contiguous precordial leads Major Exclusion Criteria: Hemorrhagic risk factors Current episode previously treated by fibrinolytics Cardiogenic shock or hemodynamically significant arrhythmias Inclusion Criteria: > 18 years of age Clinical diagnosis of AMI ( ischemic pain > 20 min. ) Onset of symptoms < 6 hours ST elevation > 1 mm in 2 contiguous limb leads or >2 mm in 2 contiguous precordial leads Major Exclusion Criteria: Hemorrhagic risk factors Current episode previously treated by fibrinolytics Cardiogenic shock or hemodynamically significant arrhythmias © TIMI Duplication prohibited by law

LAD Frame 1: Dye Touches Both Borders & Moves Forward Frame 0: Dye Touches One or No Borders Last Frame Definition Frame 21: Dye first enters landmark First Frame Definition RCA LCX Distal Landmark Normal Flow in the Absence of MI : frames 1st branch off posterolateral 1st branch off posterolateral Last branch off most distal OM Last branch off most distal OM “Whale’s tail” or “pitchfork” or most distal branch LAD at apex “Whale’s tail” or “pitchfork” or most distal branch LAD at apex Gibson, Circulation 1996; 93: TITAN: Primary Endpoint Corrected TIMI Frame Count © TIMI Duplication prohibited by law

6.2% 4.4% 2.0% n = 203 n = 46 n = 434 TMP Grade 3 p = 0.05 Mortality (%) n = % Gibson et al, Circulation 2000 Normal ground glass appearance of blush Dye mildly persistent at end of washout Normal ground glass appearance of blush Dye mildly persistent at end of washout Dye strongly persistent at end of washout Gone by next injection Dye strongly persistent at end of washout Gone by next injection Stain present Blush persists on next injection Stain present Blush persists on next injection No or minimal blush TMP Grade 2 TMP Grade 1 TMP Grade 0 TITAN Other Angiographic Efficacy Endpoint: TIMI Myocardial Perfusion (TMP) Grades © TIMI Duplication prohibited by law

TITAN-TIMI 34: Angiographic Perfusion Score Integrates epicardial and myocardial perfusion Integrates epicardial and myocardial perfusion Integrates flow before and after PCI Integrates flow before and after PCI Sum of the following: Sum of the following: TIMI Flow Grade Before PCI (0-3) TIMI Myocardial Perfusion Grade Before PCI (0-3) TIMI Flow Grade After PCI (0-3) TIMI Myocardial Perfusion Grade After PCI (0-3) Integrates epicardial and myocardial perfusion Integrates epicardial and myocardial perfusion Integrates flow before and after PCI Integrates flow before and after PCI Sum of the following: Sum of the following: TIMI Flow Grade Before PCI (0-3) TIMI Myocardial Perfusion Grade Before PCI (0-3) TIMI Flow Grade After PCI (0-3) TIMI Myocardial Perfusion Grade After PCI (0-3) Total Angiographic Perfusion Score: Gibson CM. Am Heart J Aug;148(2): Failed 0-3; Partial 4-9; Full © TIMI Duplication prohibited by law

Relationship of Angiographic Perfusion Score to SPECT Infarct Size & Mortality © TIMI Duplication prohibited by law % SPECT Infarct Size Angiographic Perfusion Score 35.5% 16.2% 12.5% p= % 1.9% 0.0% p=0.01 % Death by 30 days Gibson CM. Am Heart J Aug;148(2):

Global Perfusion Score Methodology Flow Grade: □ 0 □ 1 □ 2 □ 3 Blush Grade: □ 0 □ 1 □ 2 □ 3 Flow Grade: □ 0 □ 1 □ 2 □ 3 Blush Grade: □ 0 □ 1 □ 2 □ 3 Flow Grade: □ 0 □ 1 □ 2 □ 3 Blush Grade: □ 0 □ 1 □ 2 □ 3 Flow Grade: □ 0 □ 1 □ 2 □ 3 Blush Grade: □ 0 □ 1 □ 2 □ 3 Flow Grade: □ 0 □ 1 □ 2 □ 3 Blush Grade: □ 0 □ 1 □ 2 □ 3 Total Potential Score: 54 points © TIMI Duplication prohibited by law

TITAN-TIMI 34: Top 10 Enrolling Sites Site Name Principal Investigator Research Coordinator Enrollment1 Mount Clemens General Hospital Samer Kazziha Rebecca Richmond 37 2 Carolina Cardiology Associates, PA Steve Rohrbeck Tammy Hedrick 32 3 University of North Carolina Mauricio Cohen Kim Wood 31 4 Northridge Hospital Ivan Rokos Kanchana Karunaratne 30 5 Tri-State Medical Group, Cardiology Jeffrey Lins Gretchen Kalenak 27 6 Genesis Medical Center Nicolas Shammas Caroline Sloane 20 7 St. Joseph's Regional Medical Center Mahesh Bikkina Karen Turnbull 16 8 University Of Cincinnati Saeb Khoury Cindy Werner 15 9 Brigham and Women's Hospital Daniel Simon Rachel Monbouquette Genesis Healthcare System Abdulhay Albirini Terri Campbell 14 © TIMI Duplication prohibited by law

TITAN-TIMI 34: Top Enrolling Sites Site Name Principal Investigator Research Coordinator Enrollment11 Trinity Medical Center Aswartha Pothula Cynthia Antonio Vanderbilt University Medical Center David Zhao Dawn Myers Cardiology Associates of Mississippi Barry Bertolet Kelly Glenn MedCentral Mansfield Greg Eaton Kathy Jurden 9 15 University Hospitals of Cleveland Tom Lassar Stacey Mazzurco 9 16 Decatur Memorial Hospital Peter Katsiyiannis Rebecka Songer 7 17 West Chester Cardiology Mian Jan Cindy Brockway 7 18 Seattle Cardiovascular Research Thomas Amidon Lynn Royal 6 19 Veterans Affairs Medical Center (111C2) Saeb Khoury Jackie Edwards 5 20 Northeast Cardiology Associates Peter Ver Lee Cindy Whited 5 © TIMI Duplication prohibited by law

TITAN-TIMI 34: Baseline Characteristics © TIMI Duplication prohibited by law Characteristic ER Eptifibatide n=174 Cath Lab Eptifibatide n=142 P value Age (yrs+SD) / yrs / yrs NS Male74.7%73.2%NS Hypertension42.2%40.9%NS Hyperlipidemia32.2%31.2%NS Current smoker 49.4%40.1%NS Diabetes15.5%18.3%NS Prior MI 14.9%10.6%NS Anterior MI 35.2%39.6%NS

TITAN-TIMI 34 Primary Endpoint: Pre-PCI TIMI Frame Count © TIMI Duplication prohibited by law p < 0.05 p=0.046 adjusting for infarct location Primary Analysis: Modified Intent-to-Treat Frame Count EREptifibatide Cath Lab Eptifibatide CTFC p < (n=137) (n=168) EREptifibatide Cath Lab Eptifibatide

© TIMI Duplication prohibited by law Pre - PCI TMPG 3 (%) EREptifibatide Cath Lab Eptifibatide 24.3% 14.2% p = (41/169)(20/141) p=0.025 adjusting for infarct location Primary Analysis: Modified Intent-to-Treat TITAN-TIMI 34: Secondary Angiographic Endpoint TIMI Flow Grades Pre - PCI TIMI 2 or 3 Flow (%) EREptifibatide Cath Lab Eptifibatide 46.2% 36.6% (79/171)(52/142) TIMI 2 or 3 p = % 19% p=NS TIMI 3

TITAN-TIMI 34: Pre-PCI Flow Throughout Heart © TIMI Duplication prohibited by law Primary Analysis: Modified Intent-to-Treat EREptifibatide Cath Lab Eptifibatide Global Perfusion Score n=125 n=99 p = p = 0.03 EREptifibatide Cath Lab Eptifibatide Global Frame Count (Ave. 3 Arteries)

© TIMI Duplication prohibited by law Pre - PCI MLD (mm) EREptifibatide Cath Lab Eptifibatide p = (n=169)(n=138) Pre - PCI % Stenosis EREptifibatide Cath Lab Eptifibatide 87.5% 91.0% p = (n=169)(n=139) Primary Analysis: Modified Intent-to-Treat TITAN-TIMI 34 Pre-PCI Quantitative Angiography

© TIMI Duplication prohibited by law Post - PCI CTFC EREptifibatide Cath Lab Eptifibatide p = 0.14 Post - PCI TIMI 3 Flow (%) EREptifibatide Cath Lab Eptifibatide 86.7% 89.1% p = NS Post - PCI TMPG 3 (%) EREptifibatide Cath Lab Eptifibatide 37.0% 36.7% p = NS (47/128)(57/154) (n=138) (n=116) (137/158) (122/137) Primary Analysis: Modified Intent-to-Treat TITAN-TIMI 34 Post-PCI Flow

TITAN-TIMI 34: Full Angiographic Perfusion © TIMI Duplication prohibited by law Full Angiographic Perfusion (APS 10-12) % EREptifibatide Cath Lab Eptifibatide 21.1% 12.5% p = (32/152)(16/128) Primary Analysis: Modified Intent-to-Treat Full Angiographic Perfusion previously defined in Gibson CM. Am Heart J Aug;148(2):

TITAN-TIMI 34: Treated as Intended in Protocol Analysis © TIMI Duplication prohibited by law ER Group: Drug at least 15 minutes before 1 st injection on angio (n=127) (n=127) Cath Lab Group: Drug after 1 st injection on angio (n=114) First Injection on Angio = Time 0

© TIMI Duplication prohibited by law p = p=0.024 adjusting for infarct location Secondary Analysis: Treated per Protocol TITAN-TIMI 34 Primary Endpoint: Pre-PCI TIMI Frame Count EREptifibatide Cath Lab Eptifibatide Frame Count (n=124) (n=109) CTFC p = Cath Lab Eptifibatide EREptifibatide

FASTERFLOW TITAN-TIMI 34: Duration of Therapy and Pre-PCI TIMI Frame Count n=165 n=165 n=111 n=111 n=17 n=17 Mean TIMI Frame Count Duration of Therapy Before First Injection p = for linear trend In cath lab to 15 min prior 15 min to 60 min. prior > 60 min. prior Earlier Treatment © TIMI Duplication prohibited by law

TITAN-TIMI 34: Pre-PCI TIMI Grade 2 or 3 Flow and Full Perfusion © TIMI Duplication prohibited by law Pre - PCI TIMI 2 or 3 Flow (%) EREptifibatide Cath Lab Eptifibatide 46.8% 34.2% (59/126) (39/114) p = Secondary Analysis: Treated per Protocol Full Angiographic Perfusion (%) EREptifibatide Cath Lab Eptifibatide 23.9% 13.2% p = Full Angiographic Perfusion previously defined in Gibson CM. Am Heart J Aug;148(2): (28/117) (14/106)

© TIMI Duplication prohibited by law Death (%) EREptifibatide Cath Lab Eptifibatide Death p = NS CHF (%) EREptifibatide Cath Lab Eptifibatide n=173 n=142 Primary Analysis: Modified Intent-to-Treat TITAN-TIMI 34 Clinical Endpoints at Discharge/Day 5 CHF p = n=173 n=142

© TIMI Duplication prohibited by law Outcome ER Eptifibatide (n=174) Cath Lab Eptifibatide (n=142) P-value TIMI Major (Hgb  >5 g/dL or ICH) 1.7%3.5%NS TIMI Minor (Hgb  3-5 g/dL) 5.2%4.2%NS TIMI Major or Minor 6.9%7.8%NS Transfusion PRBC 9.8%7.0%NS Stroke or ICH 0.0%0.0%NS Thrombocytopenia (Plt. < 100K) 2.3%1.4%NS TITAN-TIMI 34: Bleeding Events Non CABG Through Discharge; Site Assessment Primary Analysis: Modified Intent-to-Treat

TITAN-TIMI 34: Conclusions © TIMI Duplication prohibited by law A strategy of early initiation of eptifibatide in the emergency room prior to primary PCI for ST segment elevation MI yields superior pre-PCI TIMI frame counts (epicardial flow) and superior TIMI myocardial perfusion compared to a strategy of initiating eptifibatide in the cardiac catheterization laboratory

TITAN-TIMI 34: Clinical Implications © TIMI Duplication prohibited by law Among patients who are to undergo primary PCI for STEMI, GP IIbIIIa inhibition should be initiated as soon as possible prior to cardiac catheterization.